Diaxonhit SA Share Price Other OTC
Equities
FR0004054427
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
24/06 | Proteomics International Laboratories Taps French Distributor for Diabetic Kidney Disease Test | MT |
08/05 | Eurobio Scientific: agreement with Myriad Genetics | CF |
Sales 2024 * | 138M 149M 12.47B | Sales 2025 * | 148M 160M 13.38B | Capitalization | 140M 151M 12.65B |
---|---|---|---|---|---|
Net income 2024 * | 9M 9.74M 813M | Net income 2025 * | 11M 11.9M 994M | EV / Sales 2024 * | 0.94 x |
Net cash position 2024 * | 9.9M 10.71M 894M | Net cash position 2025 * | 32.8M 35.49M 2.96B | EV / Sales 2025 * | 0.72 x |
P/E ratio 2024 * |
14.7
x | P/E ratio 2025 * |
11.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.91% |
Managers | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/17/19 |
Director of Finance/CFO | 43 | 01/22/01 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/17/19 |
Director/Board Member | 68 | 04/09/04 | |
Director/Board Member | 67 | 15/17/15 |
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.44B | |
+41.02% | 40.03B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.29B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |